Literature DB >> 20865452

Validation of the Fatigue Impact Scale in Hungarian patients with multiple sclerosis.

Erika Losonczi1, Krisztina Bencsik, Cecília Rajda, Gyula Lencsés, Margit Török, László Vécsei.   

Abstract

PURPOSE: Fatigue is one of the most frequent complaints of patients with multiple sclerosis (MS). The Fatigue Impact Scale (FIS), one of the 30 available fatigue questionnaires, is commonly applied because it evaluates multidimensional aspects of fatigue. The main purposes of this study were to test the validity, test-retest reliability, and internal consistency of the Hungarian version of the FIS.
METHODS: One hundred and eleven MS patients and 85 healthy control (HC) subjects completed the FIS and the Beck Depression Inventory, a large majority of them on two occasions, 3 months apart.
RESULTS: The total FIS score and subscale scores differed statistically between the MS patients and the HC subjects in both FIS sessions. In the test-retest reliability assessment, statistically, the intraclass correlation coefficients were high in both the MS and HC groups. Cronbach's alpha values were also notably high.
CONCLUSIONS: The results of this study indicate that the FIS can be regarded as a valid and reliable scale with which to improve our understanding of the impact of fatigue on the health-related quality of life in MS patients without severe disability.

Entities:  

Mesh:

Year:  2010        PMID: 20865452     DOI: 10.1007/s11136-010-9749-7

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  25 in total

1.  Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters.

Authors:  P Flachenecker; T Kümpfel; B Kallmann; M Gottschalk; O Grauer; P Rieckmann; C Trenkwalder; K V Toyka
Journal:  Mult Scler       Date:  2002-12       Impact factor: 6.312

2.  Fatigue in multiple sclerosis: relationship to depression, disability, and disease pattern.

Authors:  D C Kroencke; S G Lynch; D R Denney
Journal:  Mult Scler       Date:  2000-04       Impact factor: 6.312

3.  Modalities of fatigue in multiple sclerosis: correlation with clinical and biological factors.

Authors:  J Iriarte; M L Subirá; P Castro
Journal:  Mult Scler       Date:  2000-04       Impact factor: 6.312

4.  Clinical aspects of fatigue in multiple sclerosis.

Authors:  R Bergamaschi; A Romani; M Versino; R Poli; V Cosi
Journal:  Funct Neurol       Date:  1997 Sep-Oct

5.  The nature of fatigue in multiple sclerosis.

Authors:  H Ford; P Trigwell; M Johnson
Journal:  J Psychosom Res       Date:  1998-07       Impact factor: 3.006

6.  Validity of a French version of the fatigue impact scale in multiple sclerosis.

Authors:  M Debouverie; S Pittion-Vouyovitch; S Louis; F Guillemin
Journal:  Mult Scler       Date:  2007-09       Impact factor: 6.312

7.  Cytokine mRNA expression in patients with multiple sclerosis and fatigue.

Authors:  Peter Flachenecker; Irene Bihler; F Weber; M Gottschalk; Klaus V Toyka; Peter Rieckmann
Journal:  Mult Scler       Date:  2004-04       Impact factor: 6.312

8.  Measuring the functional impact of fatigue: initial validation of the fatigue impact scale.

Authors:  J D Fisk; P G Ritvo; L Ross; D A Haase; T J Marrie; W F Schlech
Journal:  Clin Infect Dis       Date:  1994-01       Impact factor: 9.079

9.  Fatigue in MS is associated with specific clinical features.

Authors:  C Colosimo; E Millefiorini; M G Grasso; F Vinci; M Fiorelli; T Koudriavtseva; C Pozzilli
Journal:  Acta Neurol Scand       Date:  1995-11       Impact factor: 3.209

10.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

View more
  6 in total

Review 1.  Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation.

Authors:  Arielle Kasindi; Dieu-Trang Fuchs; Yosef Koronyo; Altan Rentsendorj; Keith L Black; Maya Koronyo-Hamaoui
Journal:  Cells       Date:  2022-05-07       Impact factor: 7.666

2.  Real-World Evidence for Favourable Quality-of-Life Outcomes in Hungarian Patients with Relapsing-Remitting Multiple Sclerosis Treated for Two Years with Oral Teriflunomide: Results of the Teri-REAL Study.

Authors:  Krisztina Bencsik; Enikő Dobos; Zita Jobbágy; Adrienne Jóri Birkás; Krisztina Kovács; Mária Sátori; Gyula Lencsés; Gabor Bartok; Erika Losonczi; László Vécsei
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-13

3.  Comparison of the Psychometric Properties of Three Fatigue Scales in Persian-Speaking Patients with Multiple Sclerosis.

Authors:  Shabnam Behrangrad; Amin Kordi Yoosefinejad
Journal:  Int J MS Care       Date:  2020-02-14

Review 4.  Neurodegeneration in Multiple Sclerosis: Symptoms of Silent Progression, Biomarkers and Neuroprotective Therapy-Kynurenines Are Important Players.

Authors:  Dániel Sandi; Zsanett Fricska-Nagy; Krisztina Bencsik; László Vécsei
Journal:  Molecules       Date:  2021-06-05       Impact factor: 4.411

Review 5.  Self-report fatigue questionnaires in multiple sclerosis, Parkinson's disease and stroke: a systematic review of measurement properties.

Authors:  Roy G Elbers; Marc B Rietberg; Erwin E H van Wegen; John Verhoef; Sharon F Kramer; Caroline B Terwee; Gert Kwakkel
Journal:  Qual Life Res       Date:  2011-10-20       Impact factor: 4.147

6.  Contributing factors to health-related quality of life in multiple sclerosis.

Authors:  Tamás Biernacki; Dániel Sandi; Zsigmond Tamás Kincses; Judit Füvesi; Csilla Rózsa; Klotild Mátyás; László Vécsei; Krisztina Bencsik
Journal:  Brain Behav       Date:  2019-11-11       Impact factor: 2.708

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.